Tumour Growth Rate as a validated early radiological biomarker able to reflect treatment-induced changes in Neuroendocrine Tumours; the GREPONET-2 study.

Details

Serval ID
serval:BIB_9AC787A38DB8
Type
Article: article from journal or magazin.
Collection
Publications
Title
Tumour Growth Rate as a validated early radiological biomarker able to reflect treatment-induced changes in Neuroendocrine Tumours; the GREPONET-2 study.
Journal
Clinical cancer research
Author(s)
Lamarca A., Ronot M., Moalla S., Crona J., Opalinska M., Lopez Lopez C., Pezzutti D., Najran P., Carvalho LFDP, Bezerra ROF, Borg P., Vietti Violi N., Vidal Trueba H., de Mestier L., Schaefer N., Baudin E., Sundin A., Costa F.P., Pavel M., Dromain C.
ISSN
1078-0432 (Print)
ISSN-L
1078-0432
Publication state
In Press
Peer-reviewed
Oui
Language
english
Notes
Publication types: Journal Article
Publication Status: aheadofprint
Abstract
TGR represents the percentage change in tumour volume per month (%/m). Previous results from the GREPONET study showed that TGR measured after 3 months (TGR <sub>3m</sub> ) of starting systemic treatment (ST) or watch and wait (WW) was an early biomarker predicting progression-free survival (PFS) in NETs.
Pts from7 centres with advanced grade(G) 1/2 NETs from the pancreas(P)/small bowel(SB) initiating ST/WW were eligible. Computed tomography (CT) / magnetic resonance imaging (MRI) performed at pre-baseline, baseline and 3(+/-1) months of study entry were retrospectively reviewed. Aim-1: explore treatment-induced changes in TGR (ΔTGR <sub>3m-BL</sub> ) (paired T-test) and Aim-2: validate TGR <sub>3m</sub> (<0.8%/m vs ≥0.8%/m) as an early biomarker in an independent cohort (Kaplan-Meier/Cox Regression).
Out of 785 pts screened, 127 were eligible. Mean (SD) TGR <sub>0</sub> and TGR <sub>3m</sub> were 5.4%/m (14.9) and -1.4%/m (11.8), respectively. Mean(SD) ΔTGR <sub>3m-BL</sub> paired-difference was -6.8%/m(19.3) (p<0.001). Most marked ΔTGR <sub>3m-BL</sub> (mean (SD);p) were identified with targeted therapies (-11.3%/m(4.7);0.0237) and chemotherapy (-7.9%/m(3.4);0.0261). Multivariable analysis confirmed the absence of previous treatment (Odds Ratio (OR) 4.65 (95%CI 1.31-16.52); p-value0.018) and low TGR <sub>3m</sub> (continuous variable; OR 1.09 (95%CI 1.01-1.19); p-value0.042) to be independent predictors of radiological objective response. When the multivariable Cox Regression was adjusted to grade (p-value 0.004) and stage (p-value0.017), TGR <sub>3m</sub> ≥0.8 (vs.<0.8) maintained its significance (p<0.001), while TGR <sub>0</sub> and ΔTGR <sub>3m-BL</sub> did not. TGR <sub>3m</sub> was confirmed as an independent prognosis factor for PFS (external validation; Aim-2) (multivariable HR 2.21 (95%CI 1.21-3.70); p-value0.003).
TGR has a role as biomarker for monitoring response to therapy for early prediction of PFS and radiological objective response.
Pubmed
Create date
18/08/2019 15:58
Last modification date
29/08/2019 11:36
Usage data